Palbociclib + Sasanlimab for Kidney Cancer
Trial Summary
Do I need to stop my current medications to join the trial?
The trial requires participants to stop taking medications that are strong inhibitors or inducers of CYP3A (a liver enzyme) at least 21 days before starting the study. Herbal supplements must also be stopped 14 days before the trial begins. Other medications are not specifically mentioned, so it's best to discuss with the trial team.
What data supports the effectiveness of the drug combination Palbociclib and Sasanlimab for kidney cancer?
How is the drug combination of Palbociclib and Sasanlimab unique for kidney cancer?
The combination of Palbociclib and Sasanlimab is unique for kidney cancer as it involves a novel approach by combining a cell cycle inhibitor (Palbociclib) with an immunotherapy agent (Sasanlimab), potentially offering a new mechanism of action compared to existing treatments that primarily focus on targeting specific pathways like tyrosine kinase or mTOR.23467
What is the purpose of this trial?
Background:Kidney cancer is the 12th leading cause of cancer-related death in the United States. Some kidney tumors do not respond well to current treatments. Better treatments are needed.Objective:To test a pair of drugs (sasanlimab and palbociclib) in people with kidney cancers.Eligibility:People aged 18 years and older with kidney cancer; specifically, clear cell renal cell carcinoma (ccRCC) or papillary renal cell carcinoma (pRCC).Design:Participants will be screened. They will have a physical exam with blood tests. They will have an imaging scan and a test of their heart function. They may have a biopsy; that is, a sample of tissue will be cut from the tumor.Participants will be treated in 28-day cycles for up to 2 years.Palbociclib is a pill taken by mouth. Participants will take this drug once a day for 21 days during each 28-day treatment cycle. They will write down the dates and times they take these pills in a diary.Sasanlimab is an injection under the skin. Participants will receive this injection on the first day of each treatment cycle.Imaging scans and blood tests will be repeated throughout the treatment. Tumor biopsies may be repeated up to 3 times; these biopsies are optional.Participants will have follow-up visits every month for 3 months after treatment ends. They will continue to have imaging scans every 3 months; these scans may be done close to home. The results can be sent to researchers.Participants will remain in the study up to 6 years.
Research Team
Ramaprasad Srinivasan
Principal Investigator
National Cancer Institute (NCI)
Eligibility Criteria
Adults with advanced kidney cancer, either clear cell renal cell carcinoma (ccRCC) after checkpoint inhibitor therapy and possibly VEGF antagonist treatment, or papillary renal cell carcinoma (pRCC), which may be untreated. Participants need at least one measurable tumor lesion, good physical condition, adequate blood counts and organ function. They must agree to use effective contraception and not breastfeed during the trial.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive palbociclib orally for 21 days and sasanlimab injection on the first day of each 28-day cycle, repeated for up to 2 years
Follow-up
Participants have follow-up visits every month for 3 months after treatment ends, with imaging scans every 3 months
Long-term follow-up
Participants continue to have imaging scans every 3 months and are monitored for up to 6 years
Treatment Details
Interventions
- Palbociclib
- Sasanlimab
Palbociclib is already approved in United States, European Union, Canada, Japan for the following indications:
- HR-positive, HER2-negative advanced or metastatic breast cancer
- HR-positive, HER2-negative locally advanced or metastatic breast cancer
- HR-positive, HER2-negative advanced or metastatic breast cancer
- HR-positive, HER2-negative advanced or recurrent breast cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
National Cancer Institute (NCI)
Lead Sponsor